Document Detail

Low Molecular Weight Heparin and Aspirin for Recurrent Pregnancy Loss: Results from the Randomized, Controlled HepASA Trial.
MedLine Citation:
PMID:  19208606     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts. METHODS: The HepASA Trial was an RCT including patients with a history of RPL and at least 1 of the following: antiphospholipid antibody (aPL), an inherited thrombophilia, or antinuclear antibody. Treatment groups were stratified by aPL status and history of early versus late pregnancy losses. Patients received either LMWH/ASA or ASA alone. The primary outcome was live birth; secondary outcomes included adverse events and bone loss at the spine and femoral neck. Literature over the past 20 years was reviewed to identify comparable RCT. RESULTS: Over 4 years, 859 women with RPL were screened: 88 (10.2%) fulfilled inclusion criteria, became pregnant and were randomized to receive either LMWH/ASA orASA alone. aPL were present in 42 (47.7%) patients in each group. The trial was stopped after 4 years when an interim analysis showed no difference in live birth rates in the 2 groups, and a lower rate of pregnancy loss in the ASA only group than expected. In the LMWH/ASA group, 35/45 (77.8%) had a live birth versus 34/43 (79.1%) in the ASA only group (p = 0.71). Neither number of prior losses nor aPL status was correlated with pregnancy outcome. There were no cases of pregnancy related thrombosis in either group. Mean change in BMD did not differ by treatment group at either the lumbar spine (p = 0.57) or femoral neck (p = 0.15). RCT since 2000 for aPL positive women with RPL and similar inclusion criteria report a mean live birth rate of 75% with either LMWH or ASA. CONCLUSION: LMWH/ASA did not confer incremental benefit compared to ASA alone for this population. Regardless of treatment regimen, number of prior losses, or aPL positivity, almost 80% of women in our RPL cohort had a successful pregnancy outcome. These findings contribute to a growing body of literature that contests the emerging standard of care comprising LMWH/ASA for this population.
Laskin; Spitzer; Clark; Crowther; Ginsberg; Hawker; Kingdom; Barrett; Gent
Related Documents :
19912516 - Low molecular weight heparin to achieve live birth following unexplained pregnancy loss...
19100956 - Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss.
22364656 - Valproate and the risk for congenital malformations: is formulation and dosage regime i...
11707886 - Unresolved loss due to miscarriage: an addition to the adult attachment interview.
2044706 - Development and hormonal control of thioredoxin and the thioredoxin-reductase system in...
7899266 - Tumour-associated antigens in maternal and fetal blood.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2009-2-4
Journal Detail:
Title:  The Journal of rheumatology     Volume:  -     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-2-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, and McMaster Medical Centre, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Juvenile psoriatic arthritis: longterm outcome and differentiation from other subtypes of juvenile i...
Next Document:  Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate tox...